Kaleidoscope
Series A in 2023
Kaleidoscope is a company that designs, administers, and hosts branded scholarship and grant programs through a cloud-based marketplace. Established in 2016 and headquartered in Minneapolis, Minnesota, it connects scholarship funders with students, creating a streamlined platform that facilitates access to personalized and curated scholarship opportunities. The company's scholarship management tool aids organizations in funding future leaders, artists, and professionals by simplifying the administration of scholarship programs. This innovative approach not only reduces administrative costs but also enhances student choice, allowing for impactful program design that meets the needs of both funders and recipients.
Smart Wires Technology
Post in 2022
Smart Wires Technology, established in 2010, is a global provider of modular power flow control solutions for electricity transmission networks. Based in Union City, California, with offices in the U.S., U.K., and Australia, the company manufactures and distributes innovative products that optimize grid capacity, enhance reliability, and facilitate renewable energy integration. Its patented technology enables utilities to manage power flow, resolve congestion, accelerate grid projects, and minimize environmental impact.
Bonum Therapeutics
Series A in 2022
Bonum Therapeutics is a biopharmaceutical company focused on developing innovative protein-based drugs designed to treat various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs with regulated, context-dependent activity. These drugs are engineered to sense their local environment and transition from an inactive to an active form, allowing for targeted therapeutic effects. In addition to cancer, Bonum Therapeutics also aims to address metabolic diseases, immunological conditions, and pain management, thereby expanding its potential impact across multiple therapeutic areas.
Fervo Energy
Series C in 2022
Fervo Energy, founded in 2017 and based in San Francisco, California, specializes in the development and commercialization of next-generation geothermal power technology. The company focuses on owning, developing, and operating geothermal assets to generate clean, carbon-free energy in new locations. By leveraging innovations in geoscience, Fervo Energy aims to accelerate the transition to a sustainable energy future, positioning itself as a key player in the evolution of the electric grid. Its proprietary technology serves as a dispatchable foundation for achieving a fully clean energy system, enabling clients to enhance productivity and scalability in energy production.
Enzinc is a company focused on developing advanced rechargeable zinc-air batteries, utilizing innovative technology to enhance energy storage solutions. Their batteries, made from a zinc metal nano-sponge, provide energy levels comparable to lithium-ion batteries while being cost-effective, akin to lead-acid alternatives. Enzinc's products aim to deliver a cleaner and safer energy source for a variety of applications, capitalizing on zinc's high energy density and recyclability. This approach not only addresses energy performance but also promotes sustainability in the battery manufacturing industry.
Kaleidoscope
Series A in 2022
Kaleidoscope is a company that designs, administers, and hosts branded scholarship and grant programs through a cloud-based marketplace. Established in 2016 and headquartered in Minneapolis, Minnesota, it connects scholarship funders with students, creating a streamlined platform that facilitates access to personalized and curated scholarship opportunities. The company's scholarship management tool aids organizations in funding future leaders, artists, and professionals by simplifying the administration of scholarship programs. This innovative approach not only reduces administrative costs but also enhances student choice, allowing for impactful program design that meets the needs of both funders and recipients.
Koya Medical
Series B in 2022
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.
Good Therapeutics
Series B in 2021
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Claros Technologies
Series A in 2021
Claros Technologies is an advanced materials company that develops safe and sustainable products with zero toxic waste. It strives to lead the industry towards a holistic approach to materials design and innovation. It was founded in 2018 and is based in St Paul, Minnesota.
SOURCE, founded in 2014 and based in Scottsdale, Arizona, specializes in developing and manufacturing solar-powered devices aimed at extracting drinkable water from the atmosphere. Their innovative hydro panels employ advanced materials science to harvest water even in arid conditions, producing pure, mineralized water that is accessible via a tap. This technology caters to a wide range of applications, including industrial, commercial, residential, and community use, ensuring clean water availability virtually anywhere.
Amplyx Pharmaceuticals
Series C in 2020
Amplyx Pharmaceuticals is a small molecule drug development company focused on creating innovative therapies for life-threatening infections, particularly in patients with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in developing oral and injectable anti-infective drugs, including antifungal agents aimed at treating invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by combining them with additional small molecules. This strategy addresses critical treatment needs in hospital settings and provides effective therapy options for patients after discharge, particularly those undergoing chemotherapy and other immunosuppressive treatments.
Good Therapeutics
Series A in 2020
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Adarza BioSystems
Series D in 2020
Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.
Smart Wires Technology
Series E in 2019
Smart Wires Technology, established in 2010, is a global provider of modular power flow control solutions for electricity transmission networks. Based in Union City, California, with offices in the U.S., U.K., and Australia, the company manufactures and distributes innovative products that optimize grid capacity, enhance reliability, and facilitate renewable energy integration. Its patented technology enables utilities to manage power flow, resolve congestion, accelerate grid projects, and minimize environmental impact.
InterVene
Series B in 2019
InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.
Good Therapeutics
Series A in 2019
Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.
Fishpeople
Series B in 2017
Fishpeople Seafood is a food production company founded in 2012 and headquartered in Portland, Oregon. The company specializes in providing sustainable seafood products to grocery retailers, aiming to disrupt the traditional seafood industry with innovative offerings. Fishpeople Seafood's product range includes wild American salmon, tuna, crab, and cod, all sourced sustainably. By focusing on authentic fish meat alternatives, Fishpeople Seafood enables consumers to embrace healthier and more environmentally responsible eating habits. The company is recognized for its rapid growth and commitment to sustainability in the seafood market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.